Acadia Pharmaceuticals sell The Goldman Sachs Group, Inc.
Start price
07.08.25
/
50%
€20.93
Target price
07.08.26
€14.58
Performance (%)
-12.66%
Price
06.05.26
€18.28
Summary
This prediction is currently active. The price of Acadia Pharmaceuticals has decreased since the start of the prediction. Compared to the start price this results in a performance of -12.66%. This prediction currently runs until 07.08.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Acadia Pharmaceuticals | -3.916% | -3.916% |
| iShares Core DAX® | 0,22 % | 1,49 % |
| iShares Nasdaq 100 | 6,05 % | 16,19 % |
| iShares Nikkei 225® | 5,72 % | 11,69 % |
| iShares S&P 500 | 2,17 % | 8,06 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Acadia Pharmaceuticals diskutieren
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $15.00 to $17.00. They now have a "sell" rating on the stock.
Ratings data for ACAD provided by MarketBeat